Medical/Pharmaceuticals
Advances in Parkinson's Disease Cell Therapy: XellSmart Launches a Multicenter Phase II Clinical Trial Following Encouraging Phase I Results
SUZHOU, China, April 14, 2026 /PRNewswire/ -- In April 2026, XellSmart officially launches its multicenter Phase II registrational clinical trial of the "Clinical-Grade, Allogeneic, Off-the-Shelf, iPSC-Derived, Dopaminergic Neural Progenitor Cell Therapy (XS411) for Primary Parkinson's Disease". ...
2026-04-14 22:00
4609
TCI Biotech Returns to Vitafoods Europe 2026 with Five Provocations for the Nutraceutical Industry and a Glimpse of the Future
BARCELONA, Spain, April 14, 2026 /PRNewswire/ -- TCI Biotech, the global CDMO+ leader in health and wellness innovation, will return to Vitafoods Europe 2026 at booth 3F40, Fira Barcelona Gran Via, armed with five bold challenges to the industry's most stubborn pain points. Building on 46 years ...
2026-04-14 22:00
3793
Phrontline Biopharma Presents Preclinical Data for TJ106, a Biparatopic HER2 Dual-Payload ADC, at American Association for Cancer Research Annual Meeting 2026
Data Demonstrate Activity in HER2-Low and ADC-Resistant Tumor Models, Supporting Advancement Toward IND SHANGHAI and SUZHOU, China, April 14, 2026 /PRNewswire/ -- Phrontline Biopharma today announced the presentation of preclinical data for TJ106, a next-generation biparatopic HER2-targeting ant...
2026-04-14 21:08
3917
Clarity signs a Commercial Manufacturing Agreement for Cu-64 SAR-bisPSMA with Nucleus RadioPharma
SYDNEY, April 14, 2026 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce the signing of a Com...
2026-04-14 21:02
4033
Senhwa Biosciences Secures Strategic Backing from Global Investor GEM with Up to NT$500 Million to Accelerate AI-Driven Drug Development
TAIPEI and SAN DIEGO, April 14, 2026 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company announced today the signing of a Memorandum of Understanding (MOU) with GEM YIELD BAHAMAS LIMITED, an affiliate of the global investment firm Global Emerging Mark...
2026-04-14 15:11
4450
Boston Aesthetics Appoints Brandon Nye as Chief Executive Officer to Drive Next Phase of Commercial Growth
IRVINE, Calif., April 13, 2026 /PRNewswire/ – Boston Aesthetics today announced the appointment of Brandon Nye as Chief Executive Officer, effective immediately. Nye will lead the company's strategic growth initiatives, commercial expansion, and operating execution as Boston Aesthetics enters its...
2026-04-13 23:00
4150
Caliway's Fat Reduction Drug CBL-514 Phase 2 Clinical Results Accepted by ASJ. CBL-0204's Demonstrated Efficacy and Safety Gain Further Academic Recognition
* Clinical results from Caliway's CBL-0204 Phase 2b study of its fat reduction drug candidate CBL-514 for localized fat reduction have been accepted by theAesthetic Surgery Journal (ASJ), a leading academic journal in aesthetic medicine and plastic surgery. * Following the publication of CBL-...
2026-04-13 16:34
4762
Haisco Enters into Exclusive License Agreement with AbbVie to Develop Novel Medicines for Pain
BEIJING, April 13, 2026 /PRNewswire/ -- On April 10, 2026, Haisco Pharmaceutical Group Co., Ltd. (Ticker Code: 002653) announced that it has entered into an exclusive licensing agreement with AbbVie (NYSE: ABBV), a global biopharmaceutical company. Under the agreement, Haisco grants AbbVie the e...
2026-04-13 14:24
4153
SINGAPORE STRENGTHENS SARCOMA CARE THROUGH COORDINATED, MULTIDISCIPLINARY APPROACH
NCIS leads multi-institutional effort to develop expert multidisciplinary guidance to improve sarcoma diagnosis, referrals and outcomes SINGAPORE, April 11, 2026 /PRNewswire/ -- Singapore is strengthening its approach to sarcoma care, a rare group of bone and soft tissue cancers that disproporti...
2026-04-11 16:20
4494
Vivatides Therapeutics Announces Oversubscribed $54 Million Series A Financing to Accelerate Extrahepatic RNA Therapeutics Development
* Advancing next-generation RNA therapeutics beyond the liver through breakthrough delivery technologies SUZHOU, China and BOSTON, April 10, 2026 /PRNewswire/ -- Vivatides Therapeutics, a global biotechnology company focused on developing extrahepatic RNA-targeting therapeutics, announced the s...
2026-04-10 20:00
5452
Oricell Therapeutics Closes $110 Million Pre-IPO Financing to Accelerate Global Development of Solid Tumor CAR-T Therapies
SHANGHAI, April 9, 2026 /PRNewswire/ -- Oricell Therapeutics Holdings Limited ("Oricell"), a global clinical-stage biotechnology company pioneering innovative cancer immunotherapies,today announced the cumulative closing of a pre-IPO financing round in excess of $110 million. The round was co-led...
2026-04-10 08:00
4954
NEXTBIOMEDICAL Secures Exclusive Distribution Agreement for Nexsphere-F™ in Japan
SEOUL, South Korea, April 9, 2026 /PRNewswire/ -- NEXTBIOMEDICAL CO., LTD. (KOSDAQ: 389650), an innovative medical device company based in South Korea, announced today that it has entered into an exclusive distribution agreement in Japan with Asahi Intecc Co., Ltd., a global medical device compan...
2026-04-09 21:00
4750
DualityBio Announces China NMPA Acceptance of Biologics License Application Seeking Approval for Trastuzumab Pamirtecan for the Treatment of Unresectable or Metastatic HER2-Positive Adult Breast Cancer
SHANGHAI, April 9, 2026 /PRNewswire/ -- DualityBio ("DualityBio" or the "Company", Stock Code: 9606.HK) today announced that the Biologics License Application (BLA) for the investigational antibody-drug conjugate ("ADC") trastuzumab pamirtecan ("T-Pam", also known as DB-1303 or BNT323), has been ...
2026-04-09 19:55
5610
Portrai to Present 11 Posters on AI-Driven Spatial Transcriptomics at AACR 2026
The South Korean spatial biology company unveils new AI agents, foundation models, and spatial biomarkers for oncology drug discovery. SEOUL, South Korea, April 8, 2026 /PRNewswire/ -- Portrai, Inc. today announced it will present 11 posters highlighting its artificial intelligence and spatial t...
2026-04-08 17:50
3556
ATLATL Announces Agreement with Daiichi Sankyo to Deepen APAC Biotech Innovation
SHANGHAI, April 7, 2026 /PRNewswire/ -- ATLATL Innovation Center (hereinafter referred to as "ATLATL"), a global innovation platform for life science research and development, announced an agreement with Daiichi Sankyo to leverage ATLATL's multi-regional innovative R&D network and expertise in the...
2026-04-08 14:08
3651
Singlomics Announces First Patient Dosed in Phase I Clinical Trial of DXP-106 (IL-1RAP mAb) in China
BEIJING, April 7, 2026 /PRNewswire/ -- Singlomics Biopharmaceuticals, an innovative clinical-stage biopharmaceutical company focused on the discovery and development of antibody therapeutics for oncology, inflammation, and autoimmune diseases, today announced that the first patient has been dosed...
2026-04-07 21:00
3372
Jin Medical International Ltd. Has Regained Compliance with Nasdaq's Minimum Bid Price Requirement
CHANGZHOU, China, April 7, 2026 /PRNewswire/ -- Jin Medical International Ltd. (NASDAQ: ZJYL) ("Jin Medical", and together with all its subsidiaries and consolidated entities, the "Company"), a NASDAQ-listed leading provider of rehabilitation medical equipment, today announced that it has receive...
2026-04-07 19:00
3567
Akeso Presents Updated Data on Cadonilimab Combination Therapy in PD-(L)1 Inhibitor-Resistant Advanced NSCLC at ELCC 2026
HONG KONG, April 6, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that, at the 2026 European Lung Cancer Congress (ELCC 2026), it reported updated results with a median follow-up of 21.45 months from a prospective, open-label, single-arm, multicenter Phase Ib/II ...
2026-04-07 11:28
3892
Alar Breaks Key Barriers in Ketamine Therapy with Positive Phase 1 Results for Long-Acting Injectable ALA-3000 for Treatment-Resistant Depression
* By reducing dissociation and sedation risk, ALA-3000 may eliminate the ≥2-hour post-dose monitoring requirement, reducing clinic operating costs, improving patient throughput, and supporting a more cost-effective and reimbursement-aligned treatment model. TAICHUNG, April 6, 2026 /PRNewswire/ ...
2026-04-06 20:00
GC Biopharma Enhances IVIG Safety Profile with Advanced Prothrombotic Impurity Detection Technology
* Proprietary analytical method for precise Factor XI (FXI) measurement published in the Journal of Microbiology and Biotechnology * Novel IgG Blocker eliminates heterophilic antibody interference, ensuring clinical-grade purity and mitigating thromboembolic risks YONGIN, South Korea, April 6...
2026-04-06 14:28
Week's Top Stories
Most Reposted
Tonik Becomes the First Standalone Digital Bank in the Philippines to Achieve Profitability
[Picked up by 297 media titles]
2026-05-12 10:15
Visa amps up the music as Official Payment Partner for the Asia leg of The Weeknd's 'After Hours Til Dawn' Stadium Tour
[Picked up by 295 media titles]
2026-05-11 16:20
Avnet and HKSTP Invite Global Startups to New AI Hardware Launchpad
[Picked up by 292 media titles]
2026-05-12 10:00Hong Leong Bank Awarded Best Managed Bank in Malaysia by The Asian Banker, Group MD/CEO Kevin Lam Named Best Bank CEO in Malaysia
[Picked up by 288 media titles]
2026-05-15 17:00
Peach Blossoms Celebrates Three Massive Wins - Black Pearl Restaurant Guide 2026, Asia's 50 Best Restaurants 2026 Extended List and Tatler Best 20 Restaurants in Singapore 2026
[Picked up by 285 media titles]
2026-05-12 14:00
